Pacira BioSciences, Inc.
21.01-0.35 (-1.64%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · PCRX · USD
Key Stats
Market Cap
944.04MP/E (TTM)
-Basic EPS (TTM)
-2.75Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Pacira BioSciences posted Q2 revenue of $181.1M, up 1.7% y/y but down 3.2% q/q (derived), driven by EXPAREL's $142.9M (up 4.5% y/y) while ZILRETTA dipped to $31.3M (down 2.0% y/y). Gross margin held at 77.4%, yet operating income fell 69.9% y/y to $8.5M amid higher R&D ($28.2M, up 38.6% y/y) and SG&A ($88.6M, up 30.0% y/y), leading to a net loss of $4.8M or $(0.11) diluted EPS—antidilutive shares excluded 14.5M options and RSUs. YTD revenue rose 1.4% y/y to $350.0M with breakeven net income, reconciling to Q2 loss; EPS aligns with 45.5M diluted shares. Cash climbed to $300.5M, FCF at $36.2M (derived from $47.5M OCF minus $11.2M capex), total debt $580.5M including $202.4M 2025 notes (repaid August 2025) and $97.8M term loan (repaid July 2025). February's GQ Bio acquisition for $30.6M cash added $18.1M goodwill and $22.5M IPR&D (amortized over undisclosed life). Patent risks loom from ongoing generic challenges.
8-K
Pacira Q2 revenues rise to $181M
Pacira BioSciences reported Q2 2025 revenues of $181.1 million, up from $178.0 million last year, driven by EXPAREL net sales of $142.9 million despite volume growth offset by discounting. The company advanced its 5x30 strategy with over 50% enrollment in the Phase 2 ASCEND study for PCRX-201, a new $300 million revolving credit facility, and a ZILRETTA co-promotion deal with Johnson & Johnson MedTech. EXPAREL manufacturing efficiencies boosted gross margins. It received $28.3 million from a favorable court ruling. Full-year revenue guidance narrowed to $730-750 million.
8-K
Pacira cuts workforce, boosts EXPAREL efficiency
Pacira BioSciences decommissioned its outdated 45-liter EXPAREL manufacturing suite in San Diego on July 9, 2025, after scaling up to efficient 200-liter facilities in San Diego and Swindon that quadruple output and cut costs. This triggered a workforce cut of 71 employees, or 8% of staff, yielding $13 million in annual operating expense savings. Charges will hit Q3 2025: $2.4–2.8 million in cash severance and $5.4 million in accelerated depreciation. Efficiencies secure margins amid rising demand.
8-K
Pacira refinances debt with $300M facility
Pacira BioSciences secures $300M revolving facility with Wells Fargo, refinancing prior debt and funding operations. The five-year deal, maturing July 3, 2030, features SOFR-based rates plus spreads of 2.50%-3.25% and a $10M letter of credit sublimit. This strengthens liquidity without penalties. Lenders gain enhanced flexibility through incremental term options up to $225M.
8-K
Stockholders approve expanded incentive plan
Pacira BioSciences stockholders approved the Amended and Restated 2011 Stock Incentive Plan at the June 10, 2025 annual meeting, adding 2,500,000 shares to the pool for equity awards. This bolsters talent retention amid biotech competition, while electing directors Marcelo Bigal, Frank D. Lee, and Alethia Young—yet rejecting executive pay. Annual say-on-pay votes will continue.
IPO
Website
Employees
Sector
Industry
BCRX
BioCryst Pharmaceuticals, Inc.
7.31+0.07
BVS
Bioventus Inc.
6.77-0.17
CBDL
CBD Life Sciences Inc.
0.00+0.00
CVSI
CV Sciences, Inc.
0.03+0.00
EBS
Emergent BioSolutions Inc.
9.40-0.07
NBIX
Neurocrine Biosciences, Inc.
138.02-9.36
NSRX
Nasus Pharma Ltd.
7.75-0.65
NXEN
Nexien BioPharma, Inc.
0.01+0.00
PRFX
PainReform Ltd.
1.26-0.04
VTRS
Viatris Inc.
10.27-0.02